COVID-19 Booster: Johnson & Johnson Alurar Aiki Yanzu WHO ta goyi baya

Hukumar ta WHO ta ba da shawarar cewa ya kamata a yi allurar rigakafin watanni biyu zuwa shida bayan rigakafin farko. SAGE tana ba WHO shawara game da manufofin rigakafin rigakafi da rigakafi na duniya, kuma shawarwarinsa suna ba da jagora kan amfani da allurar rigakafin da ake bayarwa ta hanyar COVAX Facility, tsarin raba kasada na duniya don haɗar siye da rarraba daidaitattun alluran rigakafin COVID-19 ga duk ƙasashe masu shiga.          

SAGE shawarar cewa Johnson & Johnson COVID-19 maganin za a iya amfani homologue (wannan maganin) makon, ta amfani da Company ta maganin duka biyu farko alurar riga kafi da kuma kara amfani harbi. A WHO goyon bayan wani m tsarin kula da heterologous (Mix-da-wasan) makon, ta amfani da Johnson & Johnson COVID-19 maganin a matsayin mai kara amfani ga m mutane shekaru 18 shekaru da mazan da suka karbi wani izini COVID-19 maganin farko regimen.

"Yau shawarwarin daga Strategic Shawarwari Group of Masana a kan rigakafin ga World Health Organization ne m affirmation cewa Johnson & Johnson COVID-19 maganin zai iya taimaka wajen rage nauyin da cutar AIDS," ya ce Mathai Mammen, MD, Ph.D., Shugaban Duniya, Janssen Research & Development, Johnson & Johnson. "Alurar rigakafin mu na COVID-19 na ci gaba da taka muhimmiyar rawa a yakin duniya na kawo karshen wannan annoba, kuma muna maraba da wannan shawarar yayin da muke aiki tare da al'ummomin duniya don kare mutane da yawa daga COVID-19."

Shawarar SAGE na wucin gadi ya dogara ne akan inganci, aminci da bayanan rigakafi daga gwaje-gwajen asibiti na Kamfanin da kuma binciken Sisonke Phase 3b na Hukumar Kula da Kayayyakin Lafiya ta Afirka ta Kudu a Afirka ta Kudu. Lokacin da aka yi amfani da shi azaman ƙarami, biyo bayan allurar farko tare da rigakafin Johnson & Johnson COVID-19, yana ba da ƙarin kariya daga kamuwa da cuta mai saurin kamuwa da cuta, kuma gabaɗaya an jure shi sosai.

A farkon wannan shekarar SAGE ta ba da shawarar yin amfani da allurar rigakafin Johnson & Johnson COVID-19 guda ɗaya bisa ga shaida daga binciken Kamfanin na Mataki na 3 ENSEMBLE, wanda ya nuna inganci ga cututtuka masu tsanani, kuma ya nuna ƙaƙƙarfan kariya daga asibiti da ke da alaƙa da COVID-19. farawa kwanaki 28 bayan alurar riga kafi. Waɗannan bayanan sun yi daidai da babban binciken shaida na duniya da aka gudanar a Amurka, wanda ya nuna ingantaccen ingantaccen rigakafin rigakafin cututtukan da ke da alaƙa da COVID-19 da asibitoci, ba tare da wata shaida ta raguwar tasiri a tsawon lokacin binciken na watanni shida - gami da lokacin da Delta Bambance-bambancen ya zama rinjaye a Amurka (ba a samun bayanan jeri don bincike).

Johnson & Johnson tana ba da alƙawarin samar da allurai har miliyan 900 na rigakafin COVID-19 ga Tarayyar Afirka (ta hanyar African Vaccine Acquisition Trust) da COVAX, a hade, har zuwa 2022.

Alurar rigakafin Johnson & Johnson COVID-19 ya dace da daidaitaccen ajiyar allurar rigakafi da tashoshi na rarraba tare da sauƙin isarwa zuwa yankuna masu nisa. An kiyasta cewa maganin zai tsaya tsayin daka har tsawon shekaru biyu a -4°F (-20°C), kuma mafi girman watanni shida a yanayin sanyi na yau da kullun na 36° zuwa 46°F (2° zuwa 8°C). Ba za a sake daskarar da maganin COVID-19 ba idan an rarraba shi a yanayin zafi na 36°F zuwa 46°F (2°-8°C).

Alurar rigakafin Johnson & Johnson COVID-19, wanda kuma ake kira da Janssen COVID-19 Vaccine, ya sami Izinin Amfani da Gaggawa na farko (EUA) a Amurka a ranar 27 ga Fabrairu, 2021, da EUA a matsayin harbi mai ƙarfi a ranar 20 ga Oktoba. Har ila yau, ya karɓi Izinin Kasuwancin Yanayi ta Hukumar Tarayyar Turai a ranar 11 ga Maris. Hukumar ta WHO ta ba da Lissafin Amfani da Gaggawa a ranar 12 ga Maris, kuma Kamfanin ya sami shawarwarin wucin gadi kan rigakafin farko ta SAGE a ranar 17 ga Maris. A ranar 24 ga Nuwamba, Lafiyar Kanada ta amince da kamfanin guda ɗaya- allurar rigakafin COVID-19. An ba da ƙarin izini da izini da yawa a cikin ƙasashe na duniya, gami da ƙasashe 50 na Afirka, tare da ƙarin gabatar da ka'idoji.

Johnson & Johnson na ci gaba da gabatar da bayanan da suka dace ga sauran masu mulki, WHO da Kungiyoyin Ba da Shawarwari na Fasaha na Allurar rigakafi (NITAGs) a duk duniya don sanar da yanke shawara kan dabarun sarrafa rigakafin gida, kamar yadda ake bukata.

Tare da haɗin gwiwar ƙungiyoyin ilimi a Afirka ta Kudu da ma duniya baki ɗaya, Kamfanin yana kuma kimanta tasirin rigakafin COVID-19 a cikin bambance-bambancen, yanzu gami da sabon nau'in Omicron mai saurin yaduwa. Bugu da kari, Kamfanin yana bin takamaiman rigakafin Omicron kuma zai ci gaba da shi yadda ake buƙata.

Don ƙarin bayani kan hanyoyin da Kamfanin ke bi don taimakawa yaƙi da cutar, ziyarci: www.jnj.com/covid-19.

Amfani da Izini

An ba da izinin allurar Janssen COVID-19 don amfani a ƙarƙashin Izinin Amfani da Gaggawa (EUA) don yin rigakafi mai aiki don hana Cutar Coronavirus 2019 (COVID-19) wanda ke haifar da mummunar cutar numfashi ta coronavirus 2 (SARS-CoV-2).

• Tsarin allurar riga-kafi na Janssen COVID-19 Alurar riga-kafi ɗaya ce (0.5 ml) da ake gudanarwa ga mutane masu shekaru 18 da haihuwa.

• Janssen COVID-19 guda ɗaya na ƙarar maganin rigakafi (0.5 ml) ana iya ba da shi aƙalla watanni 2 bayan rigakafin farko ga mutane masu shekaru 18 da haihuwa.

• Za a iya ba da kashi ɗaya na rigakafin Janssen COVID-19 (0.5 ml) ga mutane masu shekaru 18 da haihuwa a matsayin ƙaramar haɓakawa daban-daban bayan kammala rigakafin farko tare da wani izini ko yarda da maganin COVID-19. Matsakaicin adadin alluran ƙararrawa na heterologous daidai yake da wanda aka ba da izini don ƙara adadin maganin da aka yi amfani da shi don rigakafin farko.

MUHIMMAN BAYANI AKAN KIYAYYA

ME YA KAMATA KA AMBACI GA MAI BARKA DA ALLURAR KUWA KAFIN KA SAMU ALLURAR COVID-19 JANSSEN?

Faɗa wa mai bada alurar riga kafi game da duk yanayin lafiyar ku, gami da idan kun:

• suna da duk wani rashin lafiyan halayen

• zazzabi

• suna da matsalar zubar jini ko kuma suna kan mai rage jini

• suna da rigakafi ko kuma suna kan maganin da ke shafar tsarin garkuwar jikin ku

• suna da ciki ko shirin yin ciki

• suna shayarwa

• sun sami wani maganin COVID-19

• sun taɓa suma tare da allura

WAYE YA KAMATA YA SAMU JANSSEN COVID-19 VACCINE?

Bai kamata ku sami Janssen COVID-19 Vaccine ba idan kun:

• ya yi mummunan rashin lafiyan bayan allurar baya ta wannan allurar

• ya kamu da rashin lafiya mai tsanani ga kowane sinadari na wannan maganin.

TA YAYA AKE BA JANSSEN COVID-19 VACCINE?

Za a ba ku Allurar Janssen COVID-19 a matsayin allura a cikin tsoka.

Allurar Farko: Ana gudanar da allurar Janssen COVID-19 azaman kashi ɗaya.

Adadin Ƙarfafawa:

Za'a iya yin allurar rigakafi guda ɗaya na Janssen COVID-19 aƙalla watanni biyu bayan rigakafin farko tare da Janssen COVID-19 Vaccine.

• Za a iya ba da kashi ɗaya na rigakafin Janssen COVID-19 ga mutane masu shekaru 18 da haihuwa waɗanda suka gama rigakafin farko tare da wani izini daban ko yarda da maganin COVID-19. Da fatan za a bincika tare da mai ba da lafiyar ku game da lokacin da adadin ƙarar ƙarar.

MENENE HADARIN ALJANIN COVID-19 JANSSEN?

Illolin da aka ruwaito tare da Janssen COVID-19 Vaccine sun haɗa da:

• Hanyoyin shafin allura: zafi, jajayen fata, da kumburi.

• Illolin gaba ɗaya: ciwon kai, jin kasala sosai, ciwon tsoka, tashin zuciya, zazzabi.

• Kumburi na lymph nodes.

• Jinin jini.

• Jin daɗi da ba a saba gani ba a cikin fata (kamar tingling ko jiɓin jijiya) (paresthesia), raguwar ji ko ƙima, musamman a cikin fata (hypoesthesia).

• Ringi mai dagewa a cikin kunnuwa (tinnitus).

• Zawo, amai.

Matsanancin Maganin Allergic

Akwai dama mai nisa cewa rigakafin Janssen COVID-19 na iya haifar da mummunan rashin lafiyan. Muguwar rashin lafiyan yakan faru a cikin 'yan mintoci kaɗan zuwa awa ɗaya bayan samun allurar Janssen COVID-19. Don haka, mai ba da rigakafin ku na iya tambayar ku da ku zauna a wurin da kuka karɓi maganin ku don saka idanu bayan rigakafin. Alamomin rashin lafiyar mai tsanani na iya haɗawa da:

• Wahalar numfashi

• Fuskar fuskarka da makogwaro

• bugun zuciya mai sauri

• Mummunan kurji a jikinka

• Dizziness da rauni

Jini na jini tare da ƙananan matakan platelets

Ruwan jini da ya shafi tasoshin jini a cikin kwakwalwa, huhu, ciki, da ƙafafu tare da ƙananan matakan platelet (ƙwayoyin jinin da ke taimaka wa jikin ku daina zubar jini), sun faru a wasu mutanen da suka karɓi Allurar Janssen COVID-19. A cikin mutanen da suka haɓaka waɗannan ɗigon jini da ƙananan matakan platelet, alamun sun fara kusan mako ɗaya zuwa biyu bayan alurar riga kafi. Bayar da rahoton waɗannan dunƙulewar jini da ƙananan matakan platelet ya kasance mafi girma a cikin mata masu shekaru 18 zuwa 49. Damar samun wannan ta faru tana da nisa. Ya kamata ku nemi kulawar likita nan da nan idan kuna da ɗayan alamun da ke biye bayan samun Janssen COVID-19 Vaccine:

• Numfashin numfashi,

• Ciwon kirji,

• kumburin kafa,

• Ciwon ciki mai ɗorewa,

• Ciwon kai mai tsanani ko na ci gaba ko duhun gani.

• Sauƙaƙe rauni ko ƙananan ɗigon jini a ƙarƙashin fata bayan wurin allurar.

Waɗannan ƙila ba su zama duk illolin da ke tattare da rigakafin Janssen COVID-19 ba. Mummunan sakamako da ba zato ba tsammani na iya faruwa. Har yanzu ana nazarin rigakafin Janssen COVID-19 a gwajin asibiti.

Guillain Barré ciwo

Ciwon Guillain Barré (cuta ce ta jijiyoyin jiki wanda tsarin garkuwar jiki ke lalata ƙwayoyin jijiya, yana haifar da raunin tsoka kuma wani lokacin naƙasa) ya faru a wasu mutanen da suka karɓi Allurar Janssen COVID-19. A yawancin waɗannan mutanen, alamun sun fara a cikin kwanaki 42 bayan karɓar Janssen COVID-19 Vaccine. Damar samun wannan faruwar ta ragu sosai. Yakamata ku nemi kulawar likita nan da nan idan kun sami ɗayan alamun da ke biyo bayan karɓar Janssen COVID-19 Vaccine:

• Rauni ko raɗaɗi, musamman a ƙafafu ko hannaye, wanda ke daɗa muni da yaduwa zuwa wasu sassan jiki.

• Wahalar tafiya.

• Wahala da motsin fuska, gami da magana, taunawa, ko hadiyewa.

• Gani biyu ko rashin iya motsa idanu.

• Wahala tare da sarrafa mafitsara ko aikin hanji.

ME YA KAMATA NA YI GAME DA ILLOLIN GABA?

Idan kun fuskanci mummunan rashin lafiyan, kira 9-1-1, ko je asibiti mafi kusa.

Kira mai ba da rigakafin ko mai ba da lafiyar ku idan kuna da wasu illolin da ke damun ku ko kuma ba su tafi ba.

Bayar da illolin allurar rigakafi ga FDA/CDC Tsarin Ba da Rahoto Mara Kyau (VAERS). Lambar kyauta ta VAERS ita ce 1-800-822-7967 ko bayar da rahoto akan layi zuwa https://vaers.hhs.gov/reportevent.html. Da fatan za a haɗa da "Janssen COVID-19 Vaccine EUA" a cikin layin farko na akwatin #18 na fam ɗin rahoton. Bugu da kari, zaku iya bayar da rahoton illa ga Janssen Biotech Inc. a 1-800-565-4008.

ZAN IYA SAMUN JANSSEN COVID-19 VACCINE A LOKACI DA SAURAN VACCINES?

Har yanzu ba a miƙa bayanai ga FDA kan gudanar da rigakafin Janssen COVID-19 a lokaci guda da sauran alluran rigakafi ba. Idan kuna tunanin karɓar Janssen COVID-19 Vaccine tare da wasu alluran rigakafi, tattauna zaɓin ku tare da mai ba da lafiya.